Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy
Marija Gjorgjievska, Djansel Bukovec, Sanja Mehandziska, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski · 2025
Read Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy by Marija Gjorgjievska, Djansel Bukovec, Sanja Mehandziska, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12866042.txt.
Description
Marija Gjorgjievska and co-authors link broken chromatin machinery to immunotherapy success. Their 2025 study scans tens of thousands of tumors for mutations in chromatin regulators, the proteins that package DNA and gate which genes can be read.
Tumors carrying such mutations bore heavier overall mutation loads, and stacking mutations in several regulators pushed the load higher still. Since mutation load often forecasts response to checkpoint drugs, the team checked outcomes. Patients whose tumors carried these mutations responded better to checkpoint drugs, about as well as patients with faulty DNA repair, the classic marker. The authors argue that chromatin status deserves a place beside repair status when predicting who benefits from immunotherapy, pending deeper clinical study.
Catalog record
| CREATOR | Marija Gjorgjievska, Djansel Bukovec, Sanja Mehandziska, Milan Risteski, Ivan Kungulovski, Zan Mitrev, Goran Kungulovski |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |